Cite
HARVARD Citation
Torres, F. et al. (2019). Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. European respiratory journal. 54 (4), p. . [Online].